

Toxic pustuloderma associated with clemastine therapy

A.FEIND-KOOPMANS, P.G.M.VAN DER VALK, P.M.STEIJLEN AND
P.C.M.VAN DE KERKHOF *Department of Dermatology, University Hospital, the Netherlands*

Accepted for publication 21 June 1996

Summary

Toxic pustuloderma is an acute pustular eruption of the skin occurring a few days after the initiation of treatment with the responsible drug. A case of toxic pustuloderma following treatment with the antihistamine clemastine is now reported.

Generalized pustulation is the clinical expression of various diseases, while acute and transient pustular erythema may occur following exposure to drugs. MacMillan *et al.* first described this condition in 1973¹ and Staughton *et al.*² designated it as 'toxic pustuloderma'. The acute pustulation and erythema of the disorder may be complicated by the features of vasculitis and the condition is a distinct entity, the acute and transient course being strikingly different from the more chronic dynamics of generalized pustular psoriasis and Sneddon–Wilkinson disease.^{3,4} Toxic pustuloderma has been reported most commonly following treatment with doxycycline, amoxycillin and carbamazepine.^{5,6}

Clemastine is an antihistamine which may occasionally induce cutaneous adverse effects, predominantly as an acute exanthem. Generalized clinical features such as severe fatigue, attacks of severe sweating and diarrhoea have also been described.^{7,8} In this communication a patient demonstrating toxic pustuloderma following treatment with clemastine is described.

Case report

A 41-year-old man presented with a 10-year history of eczema affecting the hands and antecubital fossae. Previous and family history did not suggest the presence of atopic dermatitis or psoriasis. Epicutaneous patch tests were negative, the serum IgE was 13 U/ml and there was no eosinophilia. The patient had just taken a 6-day course of the antihistamine clemastine at a dose of 1 mg/day for his eczema; he then stopped the clemastine after consulting his family doctor because of deterioration of

his condition. He had not been on any other medication for at least 3 months previously. Two days after discontinuing the treatment, he was seen by a dermatologist with a pustular, non-confluent eruption, along with malaise, nausea, diarrhoea and pyrexia. Two days later again, he




Figure 1. Several pin-head pustules arising within an area of wide-spread erythema.



Figure 2. Spongiform pustule with a mixed infiltrate of neutrophils and eosinophils (H&E, $\times 200$).

Correspondence: Dr Annette Feind-Koopmans, PO Box 9101, 6500 HB Nijmegen, the Netherlands.

Table 1. Dermatoses characterized by pustulation

Sneddon-Wilkinson subcorneal pustular dermatosis
Acute pustular psoriasis (von Zumbusch type)
Pustulosis palmaris et plantaris (Andrews type)
Acute generalized pustular bacteriemia
Subcorneal pustules of erythema multiforme
Subcorneal pustules of Sweet's syndrome
Impetigo herpetiformis

was admitted in very ill condition to our in-patient department with a fever of 39.5°C.

Over the face, neck, trunk and upper extremities there was a sharply demarcated erythema with numerous non-follicular, partly confluent, pinhead-sized pustules (Fig. 1). On the lower extremities the same picture was complicated by petechiae. Ill-defined erythema with crusts and pustulation was observed on the palms and volar and interdigital aspects of the fingers. The nails and mucous membranes were normal. No enlargement of tonsils or pharyngeal lymph nodes was observed. Laboratory examination

revealed a leucocytosis of $14 \times 10^9/l$ with 98% neutrophils and an erythrocyte sedimentation rate of 3 mm/h. Blood cultures were negative; however, culture of a pustule revealed a mild growth of group G *Streptococci* and *Staphylococcus aureus*, considered unlikely nevertheless to have a causal role in his generalized skin eruption.

Histopathological examination of a 4-mm punch biopsy from the skin of the thigh revealed a partly spongiotic epidermis with some intraepidermal pustules containing both eosinophils and neutrophils (Fig. 2); no acanthosis or enlargement of the rete ridges was observed. The papillary dermis was oedematous and a mixed inflammatory infiltrate of mainly lymphocytes, histiocytes and eosinophils around dermal blood vessels was seen, with some perivascular neutrophils and diapedesis of red blood cells. Prednisone was then prescribed at a dosage of 40 mg/day for 4 days; the eruption subsided within 1 week without scarring. Six months after the cutaneous reaction to clemastine, no relapse had occurred. After 4 months, epicutaneous and intracutaneous testing was carried out. The epicutaneous test was negative, but intracutaneous testing with 0.2 ml

Drug classes	Drug	Reference
Analgesics	Acetaminophen, Naproxen	9, 15
	Phenylbutazone	16
Antibiotics	Amoxycillin, Ampicillin	9-18, 19
	Cephalexin, Cefazolin	21, 22
	Cephadrine, Cefazidime	23, 28
	Cefuroxime, Chloramphenicol	28, 1
	Clindamycin, Cotrimoxazole	28, 24
	Doxycycline, Erythromycin	6-9, 9
	Gentamicin, Imipenem	28, 25
	Norfloxacin, Pristinamycin	29, 9
	Penicillin, Josamycin	9-28, 27
	Metronidazole, Isoniazid	28, 26
	Rovamycin, Spiramycin	32, 9
	Roxithromycin, Vancomycin	9, 9-28
	Trimethoprim	26
Antiepileptics	Pipemidic acid	9
	Carbamazepine	9, 30-31
Antidiabetic	Phenytoin	33
	Carbutamide	9
Anthelmintic	Piperazine	1
Antihypertensives	Nifedipine, Diltiazem	9, 34
Diuretic	Furosemide	1
Antimalarials	Hydroxychloroquine,	32-35, 1
	Pyrimethamine	
Carbonic anhydrase inhibitor	Acetazolamide	20
Expectorant	Eprazinone	36
Glucocorticoid	Prednisolone	17
Sympathomimetic	Buphenine	37
Tranquillizer	Clobazam	9
Others	Bufexamac, Disulfiram	9, 37
	Nadoxolol, 8-Methoxypsoralen	9, 38

Table 2. Drugs which may induce toxic pustuloderma

Adapted from Süß and Korting.⁵

of clemastine (1 mg/ml) in the right ventral forearm with a control of 0.2 ml saline in the left forearm produced a weal and flare reaction with a weal diameter of 28.0 mm at 10 min persisting for more than 24 h; no pustules developed. Seven healthy control subjects were tested similarly, weal size being less in them at 10.5 to 16.0 mm (mean 13.6 mm); however, the specificity of the positive provocation test in our patient is clearly not absolutely certain.

Discussion

Various dermatoses are characterized by pustulation (Table 1). Within the spectrum of such dermatoses, toxic pustuloderma has unique characteristics: (i) the time relationship between administration of the drug and the appearance of the eruption;⁸ (ii) the acute onset of the disorder with malaise and fever; (iii) the presence of spongiform superficial pustules, papillary oedema and a polymorphous perivascular infiltrate with numerous eosinophils, also present in the epidermis; (iv) signs of vasculitis;^{10,11} (v) the absence of comedones;¹² and (vi) negative bacterial and viral cultures.¹³

Recently a variety of drugs have been reported to cause generalized pustular drug rashes (Table 2), and the variability of the drug classes which may cause the condition suggests that a common pathway is likely to be responsible for this reaction pattern. The patient described in this report developed the disorder following clemastine therapy. Although we have not been able to prove a definite causal association, we feel that it is likely that the drug precipitated the condition. The pathogenesis might be either a drug-specific immune response, or else a non-immunological process.¹⁴

References

- MacMillan AL. Generalized pustular drug rash. *Dermatologica* 1973; **146**: 285–91.
- Staughton RCD, Rowland-Payne CME, Harper JI, McMichen H. Toxic pustuloderma: a new entity. *J R Soc Med* 1984; **77** (Suppl. 4): 6–8.
- Baker H. Generalized pustular psoriasis. *Br J Dermatol* 1968; **80**: 771–93.
- Sneddon IB, Wilkinson DS. Subcorneal pustular dermatosis. *Br J Dermatol* 1956; **68**: 385–94.
- Süss R, Korting HC. Generalised pustular drug rash. *Eur J Dermatol* 1994; **5**: 351–3.
- Trueb RM. Acute generalized exanthematous pustulosis due to doxycycline. *Dermatology* 1993; **186**: 75–8.
- Zürcher K, Krebs A. Psychotherapeutic drugs. In: *Cutaneous Drug Reactions*, 2nd edn. Basel: Karger, 1992: 192.
- Dukes MNG. Antihistamines. In: *Meyler's Side-effects of Drugs*, Vol. 8. Amsterdam Excerpta: Medica, 1975: 411.
- Roujeau JC. Acute generalized exanthematous pustulosis. *Arch Dermatol* 1991; **127**: 1333–8.
- Tan RSH. Acute generalized pustular bacterid. *Br J Dermatol* 1974; **91**: 209–15.
- Burrows NP, Russell-Jones R. Pustular drug eruptions: a histopathological spectrum. *Histopathology* 1993; **22**: 569–73.
- Bean SF. Acneiform eruption from tetracycline. *Br J Dermatol* 1971; **85**: 585–6.
- Rouchouse B. Acute generalized exanthematous pustular dermatitis and viral infection. *Dermatologica* 1986; **173**: 180–4.
- Wintroub BU, Stern RS, Arndt KA. Cutaneous reactions to drugs. In: Fitzpatrick TB, Eisen AZ, Wolff K *et al.*, eds. *Dermatology in General Medicine*, Vol. 2, 3rd edn. New York: McGraw-Hill, 1987: 1353–66.
- Grattan CEH. Generalized eruptive pustular drug rash due to naproxen. *Dermatologica* 1989; **179**: 57–8.
- Diaz LA, Provost TT, Tomasi TB. Pustular necrotizing angitis. *Arch Dermatol* 1973; **108**: 114–18.
- Voss M. Eine Prednison Allergie mit pustulösem Exanthem. *Dermatol Monatssch* 1988; **174**: 221–5.
- Armster H, Schwarz T. Arzneimittelreaktion auf Amoxicillin unter dem Bild eines toxischen Pustuloderms. *Hautarzt* 1991; **42**: 713–16.
- Ogino A, Tagami H, Takahashi C, Higuchi T. Generalized pustular toxic erythema: pathogenetic relationship between pustule and epidermal appendage. *Acta Derm Venerol* 1978; **58**: 257–61.
- Ogoshi M, Yamada Y, Tani M. Acute generalized exanthematous pustulosis induced by cefaclor and acetazolamide. *Dermatologica* 1992; **184**: 142–4.
- Jackson H, Vion B, Levy PM. Generalized eruptive pustular drug rash due to cephalexin. *Dermatologica* 1988; **177**: 292–4.
- Stough D, Guin JD, Baker GF, Haynie L. Pustular eruptions following administration of cefazolin: a possible interaction with methylidopa. *J Am Acad Dermatol* 1987; **16**: 1051–2.
- Kalb RE, Grossman ME. Pustular eruption following administration of cephadrine. *Cutis* 1986; **38**: 58–60.
- MacDonald KJS. Pustular dermatosis induced by cotrimoxazole. *Br J Dermatol* 1986; **293**: 1279–80.
- Escallier F, Dalac S, Foucher JL *et al.* Pustulose exanthématique aiguë généralisée. Imputabilité à l'imipinème (Tiénam). *Ann Dermatol Vénéréol* 1989; **116**: 407–9.
- Braun-Falco O, Luder Schmidt C, Maciejewski W, Scherer R. Pustulosis acuta generalisata. *Hautarzt* 1978; **29**: 371–7.
- Bernard P, Amici JM, Catanzano G *et al.* Toxidermie pustuleuse aiguë généralisée. A propos d'un cas induit par la josamycine. *Ann Dermatol Vénéréol* 1989; **116**: 31–3.
- Röckl H. Medikamentenallergische Vasculitis leucocytoclastica unter dem Bild eines generalisierten pustulösen Exanthems. *Hautarzt* 1981; **32**: 467–70.
- Shelley ED, Shelly WB. The subcorneal pustular drug eruption: an example by norfloxacin. *Cutis* 1986; **38**: 58–60.
- Commens CA, Fischer GO. Toxic pustuloderma following carbamazepine therapy. *Arch Dermatol* 1988; **124**: 178–9.
- Gebauer K, Holgate C, Navaratnam A. Toxic pustuloderma. *Australas J Dermatol* 1990; **31**: 89–93.
- Beylot C, Bioulac P, Doutre MS. Pustuloses exanthématiques aiguës généralisées. A propos de 4 cas. *Ann Dermatol Vénéréol* 1980; **107**: 37–48.
- Stanley J. Phenytoin hypersensitivity reaction. *Arch Dermatol* 1978; **118**: 308–9.
- Lambert DG, Dalac S, Beer F *et al.* Acute generalized exanthematous pustular dermatitis induced by diltiazem. *Br J Dermatol* 1988; **118**: 308–10.
- Lotem M, Ingber A, Segal R, Sandbank M. Generalized pustular drug rash induced by hydroxychloroquine. *Acta Derm Venerol* 1990; **70**: 250–1.
- Faber M, Maucher OM, Stengel R, Goertler E. Eprazinonenexanthem mit subcornealer Pustelbildung. *Hautarzt* 1984; **35**: 200–3.
- Spindler E, Janier M, Bonnin JM *et al.* Pustulose exanthématique aiguë généralisée liée à la buphénine: un cas. *Ann Dermatol Vénéréol* 1992; **119**: 273–5.
- Yip J, Sheehan-Dare R, Cotterill J. Toxic pustuloderma due to PUVA treatment. *Br J Dermatol* 1991; **125**: 401–2.

This document is a scanned copy of a printed document. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material.